WallStSmart
CATX

Perspective Therapeutics Inc.

NYSE MKT: CATX · HEALTHCARE · MEDICAL DEVICES

$3.90
-0.89% today

Updated 2026-04-30

Market cap
$514.22M
P/E ratio
P/S ratio
581.70x
EPS (TTM)
$-1.41
Dividend yield
52W range
$2 – $6
Volume
1.6M

WallStSmart proprietary scores

24
out of 100
Grade: F
Strong Sell
Investment rating
3.7
Growth
D
9.0
Quality
A+
2.5
Profitability
F
5.0
Valuation
C+
4/9
Piotroski F-Score
Moderate
3.3
Altman Z-Score
Safe zone
Industry rank
View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target
$13.00
+233.76%
12-Month target
Intrinsic (DCF)
Margin of safety
2 Strong Buy12 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths
+ Altman Z 3.31 — safe zone
+ Debt/equity 0.01x — low leverage
Risks
- Thin margins at 0.00%
- Negative free cash flow $-20.21M
- Revenue declining -43.40% QoQ

Key financials

Revenue Net Income Free Cash Flow
Metric2023202320242025TTM
Revenue$7.10M$1.43M$0.00$0.00$884000.00
Net income$-14.67M$-46.51M$-79.28M$-103.12M$-37.49M
EPS$-1.41
Free cash flow$-12.47M$-37.98M$-72.71M$-95.23M$-20.21M
Profit margin-206.50%-3,243.24%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
CATX$514.22M243.72.55.09.0Avoid
LLY$760.43B7810.010.05.06.5Strong Buy
JNJ$547.28B594.79.03.36.0-43.54%Buy
ABBV$360.63B634.08.04.75.0-29.31%Buy
UNH$336.47B545.35.57.34.8+42.09%Buy
AZN$287.11B646.78.05.35.0+4.07%Buy

Smart narrative

Perspective Therapeutics Inc. trades at $3.90. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 3.31, it sits in the safe zone. TTM revenue stands at $884000.00.

Frequently asked questions

What is Perspective Therapeutics Inc.'s stock price?
Perspective Therapeutics Inc. (CATX) trades at $3.90.
Is Perspective Therapeutics Inc. overvalued?
Smart Value Score 24/100 (Grade F, Strong Sell).
What is the price target of Perspective Therapeutics Inc. (CATX)?
The analyst target price is $13.00, representing +233.8% upside from the current price of $3.90.
What is Perspective Therapeutics Inc.'s revenue?
TTM revenue is $884000.00.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
3.31 — safe zone.

Company info

SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE MKT
CurrencyUSD

Quick metrics

P/S ratio581.70x
ROE-41.60%
Beta1.87
50D MA$4.77
200D MA$3.64
Shares out0.11B
Float0.07B
Short ratio
Avg volume1.6M

Performance

1 week-7.97%
1 month+4.91%
3 months+58.15%
YTD+55.27%
1 year
3 years
5 years